SLDB Solid Biosciences Inc. Insider Trading

SLDB CEO Cumbo Alexander sells 80,258 shares at $6.44 while company posts -40.6% annual revenue decline and $-45.8M net loss

CEO Cumbo Alexander sold 80,258 shares (80.3K shares) for $516,612.72 ($516.6K) at $6.44, reducing his holdings by 22.9% from 351,189 to 270,931 shares. This sale occurs as Solid Biosciences reports severe financial deterioration: latest quarterly revenue of $0.00, annual net income of $-45,776,000.00 ($-45.8M), and 40.6% year-over-year revenue decline. While the stock has appreciated 46.0% over the past 90 days and 18.0% over 30 days (and trades near its 52-week high of $7.07), the company remains deeply unprofitable and has contracted substantially in revenue, raising questions about the sustainability of recent gains and the strategic rationale for this significant reduction in CEO equity exposure.

SLDB director Kahn Clare purchases 1,860 shares at $5.34, tripling position to 2,960 shares amid 65.2% decline from 52-week high

Kahn Clare, a SLDB director, purchased 1,860 shares at $5.34 on 2025-03-11, increasing her holdings by 169.1% from 1,100 to 2,960 shares. The transaction occurred at a price 65.2% below the 52-week high of $14.75, though current price of $5.14 now trades slightly below the transaction price. Her prior buy at this ticker on 2024-06-07 showed a 90-day return of +10.9%, demonstrating past timing success at SLDB. However, the company's fundamentals are challenged: revenue stands at $0.00 in the latest quarter, net income is negative $-32,725,000.00, annual revenue contracted 40.6% year-over-year, and the company remained unprofitable over its most recent full fiscal year. The purchase represents a meaningful accumulation by a board member into a distressed-stage biotech with no current revenue generation, warranting detailed scrutiny into what prompted this addition to her position at this juncture.

Perceptive Advisors LLC bought 5,000,000 shares of SLDB at $4.03; prior SLDB buy posted +95.8% 90d return; 2 other insiders also bought within 14 days.

Perceptive Advisors LLC purchased 5,000,000 shares at $4.03, increasing holdings from 6,833,539 to 11,833,539 shares (+73.2%) in a substantial commitment. The insider's single prior transaction at SLDB (a buy on 2024-01-11) delivered a +95.8% 90-day return, demonstrating historical success timing at this ticker. This transaction arrives amid a cluster pattern: 2 other insiders purchased SLDB within the past 14 days. Notably, the stock has moved sharply higher since the transaction date—up +85.3% over 30 days and currently at $5.78 versus the transaction price of $4.03—though the company remains unprofitable with revenue of $0.00 (latest quarter) and net income of $-32,725,000.00, complicating assessment of fundamental justification for the coordinated buying activity.

Bain Capital Life Sciences bought 1,000,000 shares of SLDB at $4.03 on 2025-02-19, raising stake to 5.03M; cluster buy pattern with 2 other insiders in past 14 days.

Bain Capital Life Sciences, a 10% owner of Solid Biosciences, purchased 1,000,000 shares at $4.03, expanding its holdings by 24.8% and establishing a cluster buy pattern alongside 2 other insiders within a 14-day window. The company is currently unprofitable with net income of -$32.7M in its most recent full fiscal year and zero revenue in the latest quarter, reflecting a pre-commercial or distressed biotech profile. Bain's cross-ticker insider track record shows 3 prior buys with an average 30-day return of +28.0%, though a 90-day win rate of only 50.0% indicates mixed timing outcomes historically. The concurrent buying activity by multiple insiders during a period when the stock trades 60.8% below its 52-week high of $14.75 merits observation of whether this represents conviction in the asset or a liquidity/capital-management event at a distressed valuation.

Major 10% owner Adage Capital buys 252,545 shares of unprofitable SLDB at $7.56; cluster buy with 2 other insiders in 14 days

Adage Capital Management, a 10% shareholder, purchased 252,545 shares at $7.56 on 2025-02-18, increasing holdings by 6.3% to 4,248,084 shares total, while the stock is down 56.1% from its 52-week high of $14.75. The company generated $0.00 in latest-quarter revenue and reported full-year net income of $-32,725,000.00, with annual revenue declining 40.6% year-over-year. This purchase is part of a cluster pattern where 2 other insiders also bought within the past 14 days, suggesting coordinated action among multiple stakeholders. The timing of accumulation by major shareholders during a revenue-declining, cash-burning phase and sharp draw-down from peak warrants examination of whether capital deployment signals confidence in a turnaround or reflects bottom-fishing in a distressed biotech.